【摘要】 目的 观察国产苯达莫司汀+卡非佐米+地塞米松治疗复发/难治性多发性骨髓瘤（Relapse or Refractory Multiple Myeloma, RRMM）的临床疗效。方法 回顾性选取2021年10月—2023年6月在广西玉林市红十字会医院血液肿瘤科就诊的32例RRMM患者的临床资料。所有患者均使用苯达莫司汀+卡非佐米+地塞米松方案再诱导治疗。评估患者的总有效率、无进展生成期、总生存期及不良反应。结果 32例RRMM均接受国产苯达莫司汀+卡非佐米+地塞米松治疗1疗程以上，治疗中位疗程数为[4(1,8)]个，总有效率18例；≥非常好的部分缓解6例。32例患者随访中位PFS为[7.4(3.5,12.8)]个月，中位OS时间为[11.3(4.6,18.8)]个月。血液学不良反应较为常见的是中性粒细胞计数减少7例、血小板减少6例、贫血6例；非血液学不良反应中常见乏力18例、呼吸道感染6例、心脏事件5例，恶心4例及周围神经病变4例。结论 苯达莫司汀+卡非佐米+地塞米松对治疗RRMM患者是一种较好的选择，临床治疗效果较好，不良反应性较轻。更多还原

【Abstract】 Objective To observe the clinical efficacy of domestic Bendamustine+Caffezomi+Dexamethasone in the treatment of relapsed/refractory multiple myeloma(RRMM). Methods Retrospective selection of clinical data of 32 patients with Relapse or Refractory Multiple Myeloma(RRMM) who attended the Department of Hematology and Oncology, Yulin Red Cross Hospital, Guangxi, China, from October 2021 to June 2023. All patients were treated with a re induction regimen of bendamustine, cabozomib, and dexamethasone. Assess the overall response rate(ORR), progression free survival(PFS), overall survival(OS), and adverse reactions of patients. Results 32 cases of RRMM were all treated with domestic Bendamustine+Caffezomi+Dexamethasone for more than one course, with a median treatment course of [4(1,8)] and a total effective rate(ORR) of 18 cases Very good partial remission(VGPR) in 6 cases. The median follow-up PFS of 32 patients was [7.4(3.5,12.8) ] months, and the median OS time was [11.3(4.6,18.8)] months.The most common adverse reactions in hematology were a decrease in neutrophil count in 7 cases, thrombocytopenia in 6 cases, and anemia in 6 cases; Among non hematological adverse reactions, 18 cases were commonly associated with fatigue, 6 cases with respiratory infections, 5 cases with cardiac events, 4 cases with nausea, and 4 cases with peripheral neuropathy. Conclusion Bendamotine+Caffezomi+Dexamethasone is a good choice for the treatment of RRMM patients, with good clinical efficacy and mild adverse reactions.更多还原